Home Clinical Topics Cardio-Pulmonary FDA approves drug to reduce CV deaths in patients with diabetes

FDA approves drug to reduce CV deaths in patients with diabetes

On Dec. 2, the Food and Drug Administration (FDA) approved a new indication for Jardiance (empagliflozin) to reduce the risk of cardiovascular (CV) death in adult patients with type 2 diabetes mellitus and cardiovascular disease. Read more

LEAVE A REPLY

Please enter your comment!
Please enter your name here